Bio-behavioral Consequences of Appearance and Performance Enhancing Drug Use
Bio-behavioral Consequences of Appearance and Performance Enhancing Drug Use
批准号:
8269936
负责人:
THOMAS B HILDEBRANDT
金额:
$17.7万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-01 至 2013-05-31
关键词:
AdultAgeAggressive behaviorAminobutyric AcidsAnabolic steroidsAppearanceAreaArgipressinAthleticBehaviorBehavioralBiologicalCharacteristicsClinicalClinical ResearchDataDependenceDevelopmentDiseaseDrug usageDrug userEatingEducationEducational BackgroundEndocrineEnvironmentEthical IssuesEthicsExerciseFatty acid glycerol estersFunctional disorderFundingGoalsGrowthHormonalHormonesImpulsivityIndividualK-Series Research Career ProgramsKnowledgeLearningLegalLicensingLinkLongitudinal StudiesMediatingMediator of activation proteinMedicalMetabolicMethodologyMissionModelingMoodsMuscleNandroloneNeuroendocrinologyNeurosecretory SystemsNeurotransmittersPatternPerformancePersonalityPharmaceutical PreparationsPoliciesPreventive InterventionPsychiatryPublic HealthRecording of previous eventsRegulationResearchResearch PersonnelResearch Project GrantsResourcesSamplingScienceScientistSerotoninSubstance abuse problemSystemTestosteroneTimeTrainingTranslational ResearchWeightWorkadverse outcomebasebehavior changecareerclinically significantdata modelingdesigndisturbance in affectexperiencefallsimprovedinterestmalemedical schoolspatient orientedprofessorprogramsresponseself esteemskillssocialtheories
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The proposed K23 Patient-Oriented Career Development Award is designed to provide the PI with the
training necessary to study the individual variability in bio-behavioral consequences of appearance and
performance enhancing drug (APED) use. Candidate: The PI is an Assistant Professor and licensed clinical
Dsychologist currently working at the Mount Sinai School of Medicine's (MSSM's) Eating and Weight
Disorders Program. He plans to use the K23 to become an R01 funded researcher that works closely with
basic and translational scientists on the clinical, ethical, and scientific challenges presented by APED use. In
order to obtain these career goals, he will use the K23 to acquire knowledge, skills, and abilities necessary to
the study the relationship between endocrine/neuroendocrine function and agression/impulsivity among
APED users. His specific training objectives are to (a) learn the theoretical, methodological, and clinical
approaches to studying the distinction between pathological and non-pathological forms of APED use, (b)
develop a working knowledge of the theory and methodology available through translational research to
study hormone-behavior relationships, (c) acquire expertise in the theory and methodology linking hormone
dysregulation to psychiatric illness, (d) acquire greater understanding of the medical, legal, and ethical
issues associated with studying substance abuse, and (e) obtain expertise in longitudinal data modeling and
statistical analysis of biological data. Environment: The Pi's proposed training plan and career goals are
consistent with the MSSM Department of Psychiatry's mission statement to integrate translational and
clinical research, particularly in the area of neuroendocrinology. Dr. Hildebrandt has available to him a
wealth of expertise and resources available including the lab facilitates necessary to study both endocrine
and neuroendocrine functioning. Research: The most reliable psychiatric consequence to APED use is
increased impulsive aggression although a range of psychiatric disturbances have been observed. The
supervised research project will be a longitudinal study of the degree of both hormone and psychiatric
dysregulation (aggression and impulsivity) in 60 adult male APED users across time (on-cycle and off-cycle)
compared to 20 age, exercise, and education matched controls. Piecewise latent growth curve modeling will
be used to investigate changes on-cycle and off-cycle changes and the following predictors of change will be
explored: APED characteristics (amount, duration, and pattern), Age, Psychiatric History, Personality, &
History of APED use). Relevance: Findings from the proposed study will help identify both the endocrine
dysfunction responsible for the psychiatric consequences to APED use and the user characteristics
predictive of these psychiatric consequences. Implications of this research are to inform prevention,
intervention, and policy based decisions related to this growing public health concern.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Body checking behaviors in men.
男性的身体检查行为。
DOI:
10.1016/j.bodyim.2009.05.001
发表时间:
2009
期刊:
Body image
影响因子:
5.2
作者:
[Walker,DCatherine, Anderson,DrewA, Hildebrandt,Thomas]
通讯作者:
Hildebrandt,Thomas
DOI:
10.1016/j.cpr.2010.04.011
发表时间:
2010-08
期刊:
CLINICAL PSYCHOLOGY REVIEW
影响因子:
12.8
作者:
[Hildebrandt, Tom, Alfano, Lauren, Tricamo, Michelle, Pfaff, Donald W.]
通讯作者:
Pfaff, Donald W.
DOI:
10.3389/fpsyg.2018.00390
发表时间:
2018
期刊:
Frontiers in psychology
影响因子:
3.8
作者:
[Hildebrandt T, Heywood A, Wesley D, Schulz K]
通讯作者:
Schulz K
DOI:
10.1016/j.soard.2014.03.012
发表时间:
2014-09
期刊:
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
影响因子:
--
作者:
[Sysko R, Hildebrandt TB, Kaplan S, Brewer SK, Zitsman JL, Devlin MJ]
通讯作者:
Devlin MJ
DOI:
10.1002/erv.1044
发表时间:
2011-01
期刊:
EUROPEAN EATING DISORDERS REVIEW
影响因子:
5.3
作者:
[Sysko, Robyn, Hildebrandt, Tom]
通讯作者:
Hildebrandt, Tom
共 8 条
A Confirmatory Efficacy Study of Interoceptive Exposure for Adolescents with Low Weight Eating Disorders
-
批准号:10571565
-
项目类别:
-
资助金额:$78.62万
-
财政年份:2023
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
General Brain Arousal and Risk for Eating Disorder
-
批准号:10365378
-
项目类别:
-
资助金额:$43.41万
-
财政年份:2021
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
General Brain Arousal and Risk for Eating Disorder
-
批准号:10656518
-
项目类别:
-
资助金额:$40.12万
-
财政年份:2021
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
Noom Coach for Bariatric Surgery
-
批准号:9464753
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2017
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
Reward Systems and Food Avoidance in Adolescents with Low Weight Eating Disorders
-
批准号:9334942
-
项目类别:
-
资助金额:$59.42万
-
财政年份:2016
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
Reward Systems and Food Avoidance in Adolescents with Low Weight Eating Disorders
-
批准号:10222953
-
项目类别:
-
资助金额:$22.09万
-
财政年份:2016
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters
-
批准号:8521678
-
项目类别:
-
资助金额:$34.37万
-
财政年份:2013
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters
-
批准号:8665495
-
项目类别:
-
资助金额:$33.03万
-
财政年份:2013
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
Bio-behavioral Consequences of Appearance and Performance Enhancing Drug Use
-
批准号:7530230
-
项目类别:
-
资助金额:$17.67万
-
财政年份:2008
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
Bio-behavioral Consequences of Appearance and Performance Enhancing Drug Use
-
批准号:8081856
-
项目类别:
-
资助金额:$17.7万
-
财政年份:2008
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
Bio-behavioral Consequences of Appearance and Performance Enhancing Drug Use
-
批准号:7660530
-
项目类别:
-
资助金额:$17.7万
-
财政年份:2008
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
Bio-behavioral Consequences of Appearance and Performance Enhancing Drug Use
-
批准号:7848976
-
项目类别:
-
资助金额:$17.7万
-
财政年份:2008
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
Assessment of Appearance and Performance Enhancing Drug Use
-
批准号:7501901
-
项目类别:
-
资助金额:$8.93万
-
财政年份:2007
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
Assessment of Appearance and Performance Enhancing Drug Use
-
批准号:7186844
-
项目类别:
-
资助金额:$9.06万
-
财政年份:2007
-
负责人:THOMAS B HILDEBRANDT
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: